Procept BioRobotics reported third quarter 2026 revenue of $98.3 million, missing analyst expectations of $100.52 million. The net loss widened to $0.46 per share, falling short of the estimated $0.39 loss. Despite the headline misses, the company highlighted a significant acceleration in the replacement cycle for its HYDROS systems and reaffirmed its full-year 2026 financial guidance.
Key Highlights
- U.S. procedure volume grew 22% year-over-year to over 13,400, supported by the delivery of 62 HYDROS systems during the quarter.
- U.S. handpiece average selling prices increased 12% to $3,570, driving a 21% increase in domestic consumable revenue to $53.9 million.
- International revenue remains a high-growth segment, increasing 32% year-over-year to $12.5 million while gross margins expanded 100 basis points to 66%.